menu search

TMBR / Why Is Timber Pharmaceuticals (TMBR) Stock Up 61% Today?

Why Is Timber Pharmaceuticals (TMBR) Stock Up 61% Today?
Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is taking off on Friday after getting an orphan drug designation in Europe. That comes from the EC and covers TMB-001 for the treatment of X-linked recessive ichthyosis. Read More
Posted: Feb 24 2023, 11:57
Author Name: InvestorPlace
Views: 110757

TMBR News  

Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up

By Zacks Investment Research
August 22, 2023

Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up

Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million. more_horizontal

Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?

By InvestorPlace
August 21, 2023

Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?

Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is undergoing a massive rally on Monday after announcing that Leo US is acquiring it in a $36 million de more_horizontal

Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001

By Zacks Investment Research
June 8, 2023

Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001

Timber (TMBR) receives a dermal carcinogenicity waiver from the FDA for TMB-001, which is being developed to treat moderate-to-severe subtypes of cong more_horizontal

Bears are Losing Control Over Timber Pharmaceuticals, Inc. (TMBR), Here's Why It's a 'Buy' Now

By Zacks Investment Research
April 14, 2023

Bears are Losing Control Over Timber Pharmaceuticals, Inc. (TMBR), Here's Why It's a 'Buy' Now

Timber Pharmaceuticals, Inc. (TMBR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In more_horizontal

Why Is Timber Pharmaceuticals (TMBR) Stock Up 61% Today?

By InvestorPlace
February 24, 2023

Why Is Timber Pharmaceuticals (TMBR) Stock Up 61% Today?

Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is taking off on Friday after getting an orphan drug designation in Europe. That comes from the EC and more_horizontal

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

By GlobeNewsWire
October 7, 2021

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE America more_horizontal

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

By GlobeNewsWire
October 7, 2021

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE America more_horizontal

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

By GlobeNewsWire
October 7, 2021

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE America more_horizontal


Search within

Pages Search Results: